celecoxib has been researched along with Cardiovascular Diseases in 144 studies
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "For this industry-independent, double-blind, double-dummy, randomised trial done in one academic hospital in Hong Kong, we screened patients with arthritis and cardiothrombotic diseases who were presenting with upper gastrointestinal bleeding, were on NSAIDs, and require concomitant aspirin." | 9.24 | Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. ( Au, KWL; Chan, FKL; Chan, H; Cheong, PK; Ching, JYL; Kee, KM; Kyaw, MH; Lam, K; Lee, V; Lo, A; Ng, SC; Suen, BY; Tse, YK; Wong, GLH; Wong, VWS; Wu, JCY, 2017) |
| "Patients who required NSAIDs for osteoarthritis or rheumatoid arthritis and were at increased cardiovascular risk were randomly assigned to receive celecoxib, ibuprofen, or naproxen." | 9.22 | Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. ( Bao, W; Beckerman, B; Berger, MF; Borer, JS; Gaffney, M; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Ruschitzka, F; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2016) |
| "The Selenium and Celecoxib Trial was a randomized, placebo-controlled trial of once-daily selenium 200 µg and celecoxib 400 mg, alone or together, for colorectal adenoma prevention." | 9.22 | Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial. ( Ahnen, DJ; Alberts, DS; Ashbeck, EL; Bhattacharyya, A; Boland, CR; Buckmeier, J; Chow, SH; Fales, L; Fay, DE; Hamilton, SR; Heigh, RI; Hsu, CH; Jacobs, ET; Lance, P; Martinez, EM; Roe, DJ; Thompson, PA; Wang, F, 2016) |
| "Chemoprevention trials have shown that celecoxib reduces adenoma recurrence but can cause cardiovascular toxicity." | 9.17 | Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study. ( Arber, N; Coghill, AE; Duggan, D; Galazan, L; Gigic, B; Hummler, S; Kazanov, D; Kotzmann, J; Kraus, S; Makar, KW; Naumov, I; Poole, EM; Scherer, D; Toriola, AT; Ulrich, CM, 2013) |
| " The Adenoma Prevention with Celecoxib (APC) trial showed that the anti-inflammatory drug celecoxib prevents recurrence of colorectal adenoma but increases risk of cardiovascular events." | 9.15 | C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. ( Bertagnolli, MM; Chan, AT; Hawk, ET; Ridker, PM; Sima, CS; Zauber, AG, 2011) |
| "The Adenoma Prevention with Celecoxib Trial examined the efficacy and safety of the cyclooxygenase (Cox)-2 inhibitor, celecoxib, for sporadic colorectal adenoma prevention in patients at high risk for colorectal cancer." | 9.14 | Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. ( Bagheri, D; Bertagnolli, MM; Breazna, A; Burn, J; Chung, DC; Collins, NT; Dewar, T; Eagle, CJ; Foley, TR; Hawk, ET; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Sylwestrowicz, T; Tang, J; Umar, A; Zauber, AG, 2009) |
| " Postmenopausal metastatic breast cancer patients without previous adjuvant AI treatment received exemestane 25 mg/days plus either celecoxib 400 mg twice daily or placebo." | 9.14 | Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. ( Bachelot, T; Crétin, J; Debled, M; Delozier, T; Falandry, C; Freyer, G; Mauriac, L; Mille, D; Pujade-Lauraine, E; Romestaing, P; You, B, 2009) |
| "To evaluate the long-term risk of gastroduodenal ulcer and cardiovascular events induced by celecoxib in a population-based, randomized, double-blind, placebo-controlled study." | 9.13 | Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. ( Feng, GS; Lam, SK; Li, J; Li, JY; Liu, WD; Ma, JL; Pan, KF; Shen, L; Wong, BC; Xia, HH; You, WC; Zhang, L; Zhang, XD, 2008) |
| "The Adenoma Prevention With Celecoxib (APC) trial studied celecoxib 200 mg twice daily and 400 mg twice daily and the Prevention of Spontaneous Adenomatous Polyps (PreSAP) trial used 400 mg once daily totest the efficacy and safety of celecoxib against placebo in reducing colorectal adenoma recurrence after polypectomy." | 9.12 | Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. ( Arber, N; Bertagnolli, MM; Eagle, C; Finn, P; Fowler, R; Hawk, E; Lechuga, M; Levin, B; McMurray, JJ; Pfeffer, MA; Solomon, SD; Wittes, J; Zauber, AG, 2006) |
| "We randomly assigned patients who had adenomas removed before study entry to receive placebo (679 patients) or 200 mg (685 patients) or 400 mg (671 patients) of celecoxib twice daily." | 9.12 | Celecoxib for the prevention of sporadic colorectal adenomas. ( Anderson, WF; Bagheri, D; Bertagnolli, MM; Boisserie, F; Burn, J; Chung, DC; Corle, D; Dewar, T; Eagle, CJ; Foley, TR; Gordon, GB; Hawk, ET; Hess, TM; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Solomon, SD; Sylwestrowicz, T; Tang, J; Viner, JL; Wittes, J; Woloj, GM; Zauber, AG, 2006) |
| "The use of 400 mg of celecoxib once daily significantly reduced the occurrence of colorectal adenomas within three years after polypectomy." | 9.12 | Celecoxib for the prevention of colorectal adenomatous polyps. ( Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M, 2006) |
| "The current use of celecoxib is associated with an increased risk of acute pancreatitis." | 7.81 | Use of celecoxib correlates with increased relative risk of acute pancreatitis: a case-control study in Taiwan. ( Hung, HC; Hung, SC; Hung, SR; Lai, SW; Lin, CL, 2015) |
| "For patients at high risk of colorectal cancer, statins do not protect against colorectal neoplasms and may even increase the risk of developing colorectal adenomas." | 6.75 | Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. ( Bertagnolli, MM; Eagle, CJ; Hawk, ET; Hsu, M; Zauber, AG, 2010) |
| " Low solubility and bioavailability issues related with celecoxib lead to the development and advancement in the discovery and research of some possible formulation administered either orally, topically or via transdermal route." | 6.66 | A journey of celecoxib from pain to cancer. ( Purohit, P; Saxena, P; Sharma, PK, 2020) |
| "Twenty-four thousand eighty-one patients who required NSAIDs for osteoarthritis or rheumatoid arthritis (RA) and had increased CV risk randomly received celecoxib, ibuprofen, or naproxen." | 5.51 | Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial. ( Bao, W; Davey, DA; Husni, E; Libby, P; Lüscher, TF; Nissen, SE; Obeid, S; Ruschitzka, F; Walker, C; Wang, Q; Wisniewski, LM; Wolski, KE; Xia, F, 2022) |
| "Celecoxib was neutral regarding CVD risk in AS patients." | 5.46 | Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study. ( Chen, CH; Chiou, JY; Leong, PY; Li, YC; Ma, CM; Tam, HW; Wang, YH; Wei, JC; Yeo, KJ, 2017) |
| "Celecoxib was not shown to reduce the risk of recurrence in intermediate- or high-risk non-muscle-invasive bladder cancer (NMIBC), although celecoxib was associated with delayed time to recurrence in pT1 NMIBC patients." | 5.30 | BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). ( Andrews, S; Blazeby, J; Bogle, R; Brough, R; Burnett, S; Cresswell, J; Cruickshank, C; Hall, E; Huddart, R; Johnson, M; Kelly, JD; Madaan, S; Maynard, L; Mostafid, H; Palmer, A; Porta, N; Protheroe, A; Tan, WS, 2019) |
| "To determine the relative risks of cardiovascular (CV), gastrointestinal (GI), and renal adverse events during long-term treatment with celecoxib, compared with ibuprofen and naproxen, in patients with osteoarthritis (OA) and patients with rheumatoid arthritis (RA)." | 5.27 | Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial. ( Bao, W; Berger, MF; Borer, JS; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2018) |
| "For this industry-independent, double-blind, double-dummy, randomised trial done in one academic hospital in Hong Kong, we screened patients with arthritis and cardiothrombotic diseases who were presenting with upper gastrointestinal bleeding, were on NSAIDs, and require concomitant aspirin." | 5.24 | Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. ( Au, KWL; Chan, FKL; Chan, H; Cheong, PK; Ching, JYL; Kee, KM; Kyaw, MH; Lam, K; Lee, V; Lo, A; Ng, SC; Suen, BY; Tse, YK; Wong, GLH; Wong, VWS; Wu, JCY, 2017) |
| "The Selenium and Celecoxib Trial was a randomized, placebo-controlled trial of once-daily selenium 200 µg and celecoxib 400 mg, alone or together, for colorectal adenoma prevention." | 5.22 | Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial. ( Ahnen, DJ; Alberts, DS; Ashbeck, EL; Bhattacharyya, A; Boland, CR; Buckmeier, J; Chow, SH; Fales, L; Fay, DE; Hamilton, SR; Heigh, RI; Hsu, CH; Jacobs, ET; Lance, P; Martinez, EM; Roe, DJ; Thompson, PA; Wang, F, 2016) |
| "Patients who required NSAIDs for osteoarthritis or rheumatoid arthritis and were at increased cardiovascular risk were randomly assigned to receive celecoxib, ibuprofen, or naproxen." | 5.22 | Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. ( Bao, W; Beckerman, B; Berger, MF; Borer, JS; Gaffney, M; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Ruschitzka, F; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2016) |
| "Chemoprevention trials have shown that celecoxib reduces adenoma recurrence but can cause cardiovascular toxicity." | 5.17 | Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study. ( Arber, N; Coghill, AE; Duggan, D; Galazan, L; Gigic, B; Hummler, S; Kazanov, D; Kotzmann, J; Kraus, S; Makar, KW; Naumov, I; Poole, EM; Scherer, D; Toriola, AT; Ulrich, CM, 2013) |
| " The Adenoma Prevention with Celecoxib (APC) trial showed that the anti-inflammatory drug celecoxib prevents recurrence of colorectal adenoma but increases risk of cardiovascular events." | 5.15 | C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. ( Bertagnolli, MM; Chan, AT; Hawk, ET; Ridker, PM; Sima, CS; Zauber, AG, 2011) |
| "The Adenoma Prevention with Celecoxib Trial examined the efficacy and safety of the cyclooxygenase (Cox)-2 inhibitor, celecoxib, for sporadic colorectal adenoma prevention in patients at high risk for colorectal cancer." | 5.14 | Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. ( Bagheri, D; Bertagnolli, MM; Breazna, A; Burn, J; Chung, DC; Collins, NT; Dewar, T; Eagle, CJ; Foley, TR; Hawk, ET; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Sylwestrowicz, T; Tang, J; Umar, A; Zauber, AG, 2009) |
| " Postmenopausal metastatic breast cancer patients without previous adjuvant AI treatment received exemestane 25 mg/days plus either celecoxib 400 mg twice daily or placebo." | 5.14 | Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. ( Bachelot, T; Crétin, J; Debled, M; Delozier, T; Falandry, C; Freyer, G; Mauriac, L; Mille, D; Pujade-Lauraine, E; Romestaing, P; You, B, 2009) |
| "To evaluate the long-term risk of gastroduodenal ulcer and cardiovascular events induced by celecoxib in a population-based, randomized, double-blind, placebo-controlled study." | 5.13 | Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. ( Feng, GS; Lam, SK; Li, J; Li, JY; Liu, WD; Ma, JL; Pan, KF; Shen, L; Wong, BC; Xia, HH; You, WC; Zhang, L; Zhang, XD, 2008) |
| "The use of 400 mg of celecoxib once daily significantly reduced the occurrence of colorectal adenomas within three years after polypectomy." | 5.12 | Celecoxib for the prevention of colorectal adenomatous polyps. ( Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M, 2006) |
| "The Adenoma Prevention With Celecoxib (APC) trial studied celecoxib 200 mg twice daily and 400 mg twice daily and the Prevention of Spontaneous Adenomatous Polyps (PreSAP) trial used 400 mg once daily totest the efficacy and safety of celecoxib against placebo in reducing colorectal adenoma recurrence after polypectomy." | 5.12 | Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. ( Arber, N; Bertagnolli, MM; Eagle, C; Finn, P; Fowler, R; Hawk, E; Lechuga, M; Levin, B; McMurray, JJ; Pfeffer, MA; Solomon, SD; Wittes, J; Zauber, AG, 2006) |
| "We randomly assigned patients who had adenomas removed before study entry to receive placebo (679 patients) or 200 mg (685 patients) or 400 mg (671 patients) of celecoxib twice daily." | 5.12 | Celecoxib for the prevention of sporadic colorectal adenomas. ( Anderson, WF; Bagheri, D; Bertagnolli, MM; Boisserie, F; Burn, J; Chung, DC; Corle, D; Dewar, T; Eagle, CJ; Foley, TR; Gordon, GB; Hawk, ET; Hess, TM; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Solomon, SD; Sylwestrowicz, T; Tang, J; Viner, JL; Wittes, J; Woloj, GM; Zauber, AG, 2006) |
| "Subjects 18 years or older with osteoarthritis, without gastroduodenal ulcer or erosive esophagitis at baseline endoscopy, and a cardiovascular indication for prophylaxis low-dose (81 or 325 mg) aspirin were prescribed open-label aspirin and blindly randomized to celecoxib 200 mg/day or naproxen 500 mg twice daily plus lansoprazole 30 mg once daily." | 5.12 | Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. ( Amer, F; Cryer, B; Goldstein, JL; Hunt, B, 2007) |
| "Celecoxib is the first COX-2-specific inhibitor approved for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as for treatment of familial adenomatous polyposis." | 4.80 | Celecoxib clinical profile. ( Tive, L, 2000) |
| "Targeted and untargeted metabolomics were used to investigate the effect of COX-2 deletion or inhibition in mice and in osteoarthritis patients exposed to nonsteroidal anti-inflammatory drugs on the l-arginine/nitric oxide pathway." | 3.88 | Cyclooxygenase-2, Asymmetric Dimethylarginine, and the Cardiovascular Hazard From Nonsteroidal Anti-Inflammatory Drugs. ( Briggs, WTE; Castro, C; FitzGerald, GA; Griffin, JL; Karlson, EW; Lahens, NF; Li, X; Malik, D; Meng, H; Rhoades, SD; Ricciotti, E; Sparks, JA; Tang, SY; Weljie, AM; West, JA, 2018) |
| "We used the National Health Insurance Service-National Sample Cohort (NHIS-NSC) to investigate patients over 20 years old with osteoarthritis and rheumatoid arthritis who received a single prescription of SKI306X, celecoxib or naproxen at least once from January 1, 2011 through December 31, 2012." | 3.85 | Evaluation of cardiovascular risk associated with SKI306X use in patients with osteoarthritis and rheumatoid arthritis. ( Hyun, MK; Woo, Y, 2017) |
| "The current use of celecoxib is associated with an increased risk of acute pancreatitis." | 3.81 | Use of celecoxib correlates with increased relative risk of acute pancreatitis: a case-control study in Taiwan. ( Hung, HC; Hung, SC; Hung, SR; Lai, SW; Lin, CL, 2015) |
| " Naproxen users had the lowest adjusted rates of serious coronary heart disease (myocardial infarction, coronary heart disease death) and serious cardiovascular disease (myocardial infarction, stroke)/death from any cause, with respective incidence rate ratios (relative to NSAID nonusers) of 0." | 3.75 | Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. ( Arbogast, PG; Castellsague, J; Chung, CP; Daugherty, JR; García-Rodríguez, LA; Murray, KT; Ray, WA; Stein, CM; Varas-Lorenzo, C, 2009) |
| "Although evidence suggests that aspirin and celecoxib may reduce the risk of esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus (BE), these drugs can also cause harmful side effects." | 3.74 | Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus. ( Broughton, DE; Gazelle, GS; Hur, C; Nishioka, NS; Ozanne, E; Yachimski, P, 2008) |
| "To estimate the net cardiovascular (CV) (coronary heart disease, stroke, congestive heart failure), and gastrointestinal (GI) (peptic ulcer complications) risk-benefit public health impact of the use of celecoxib compared to non-selective NSAIDs in the arthritis population." | 3.74 | Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. ( Castellsague, J; Maguire, A; Perez-Gutthann, S; Varas-Lorenzo, C, 2007) |
| "Using national data (2001-2003), this study explored the risk of acute myocardial infarction (AMI), angina, stroke and transient ischaemic attack (TIA) in long-term users of rofecoxib and celecoxib in Taiwan and compared this data with that for those using meloxicam." | 3.73 | Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study. ( Hsiao, FY; Huang, WF; Shih, YT; Tsai, YW; Wen, YW, 2006) |
| " The risk score was designed to predict the 1-year occurrence of major toxicity among NSAID users, including major adverse cardiovascular events, acute kidney injury, significant gastrointestinal events, and mortality." | 2.90 | Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial. ( Husni, ME; Nissen, S; Paynter, N; Shao, M; Solomon, DH; Wolski, K, 2019) |
| "CG100649 is a novel NSAID proposed to inhibit both COX-2 and carbonic anhydrase (CA)-I/-II." | 2.77 | Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649. ( Alamuddin, N; Cen, L; Fitzgerald, GA; Lawson, JA; Propert, KJ; Skarke, C, 2012) |
| "For patients at high risk of colorectal cancer, statins do not protect against colorectal neoplasms and may even increase the risk of developing colorectal adenomas." | 2.75 | Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. ( Bertagnolli, MM; Eagle, CJ; Hawk, ET; Hsu, M; Zauber, AG, 2010) |
| "Celecoxib use was associated with a dose-related increase in the composite end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure." | 2.71 | Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. ( Anderson, WF; Bertagnolli, M; Finn, P; Fowler, R; Hawk, E; McMurray, JJ; Pfeffer, MA; Solomon, SD; Wittes, J; Zauber, A, 2005) |
| " Low solubility and bioavailability issues related with celecoxib lead to the development and advancement in the discovery and research of some possible formulation administered either orally, topically or via transdermal route." | 2.66 | A journey of celecoxib from pain to cancer. ( Purohit, P; Saxena, P; Sharma, PK, 2020) |
| "Inflammation is a biological function which triggered after the mechanical tissue disruption or from the responses by the incidence of physical, chemical or biological negotiator in body." | 2.61 | Human disorders associated with inflammation and the evolving role of natural products to overcome. ( Kishore, N; Kumar, P; Shanker, K; Verma, AK, 2019) |
| "Cyclooxygenase inhibitors represented extremely promising novel anti-inflammatory drugs until one of them, rofecoxib (Vioxx), was found to be associated with increased cardiovascular morbidity; however, another such drug, celecoxib (Celebrex), suffers far less from this side effect for unknown reasons and is still widely used." | 2.45 | An ion channel hypothesis to explain divergent cardiovascular safety of cyclooxygenase-2 inhibitors: the answer to a hotly debated puzzle? ( Shapiro, MS, 2009) |
| " Patients at highest baseline risk demonstrated disproportionately greater risk of celecoxib-related adverse events (P for interaction=0." | 2.44 | Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. ( Arber, N; Arndt, G; Bertagnolli, MM; Chew, EY; Finn, PV; Fowler, R; Goss, PE; Hawk, E; Kim, J; Lance, P; Levin, B; Martin, B; Meinert, CL; Obara, S; Pater, JL; Solomon, SD; Viner, J; Wittes, J, 2008) |
| " The cardiovascular risks of COX-2 inhibitors appear heterogeneous, influenced not only by the drug class, but also individual drug, dosage and patient characteristics." | 2.43 | Celecoxib and cardiovascular risks. ( Brophy, JM, 2005) |
| "Celecoxib was not associated with an elevated risk of vascular occlusion, summary relative risk 1." | 2.43 | Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. ( Henry, D; McGettigan, P, 2006) |
| " Patients prescribed CSIs (or NSAIDs) should be reviewed within the first few weeks of therapy to assess effectiveness, identify adverse effects and determine the need for ongoing therapy." | 2.41 | Considerations for the safe prescribing and use of COX-2-specific inhibitors. ( , 2002) |
| "Diclofenac has increased cardiovascular risks, but its risk profile compared with other COX-2 inhibitors remains unknown." | 1.72 | Cardiovascular Risks of Diclofenac Versus Other Older COX-2 Inhibitors (Meloxicam and Etodolac) and Newer COX-2 Inhibitors (Celecoxib and Etoricoxib): A Series of Nationwide Emulated Trials. ( Pedersen, L; Schmidt, M; Sørensen, HT, 2022) |
| "The large number of reports that involved a concomitant medicine that was in contravention with prescribing guidelines indicates an increased need for efforts to support the safe prescribing of celecoxib." | 1.51 | Potentially inappropriate concomitant medicine use with the selective COX-2 inhibitor celecoxib: Analysis and comparison of spontaneous adverse event reports from Australia, Canada and the USA. ( Ahmed, R; Baselyous, Y; De Cocinis, M; Ibrahim, M; Kalra, A; Yacoub, R, 2019) |
| "Celecoxib was neutral regarding CVD risk in AS patients." | 1.46 | Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study. ( Chen, CH; Chiou, JY; Leong, PY; Li, YC; Ma, CM; Tam, HW; Wang, YH; Wei, JC; Yeo, KJ, 2017) |
| "examined Barrett's esophagus patient preferences for cancer chemoprevention with either aspirin or celecoxib." | 1.35 | Chemoprevention and Barrett's esophagus: decisions, decisions. ( Falk, GW; Jankowski, J, 2008) |
| " In conclusion, our study suggests that chronic administration of celecoxib may have a damaging effect on kidney, as evident through altered histopathology and renal functions." | 1.34 | Role of oxidative stress in celecoxib-induced renal damage in wistar rats. ( Aggarwal, R; Agnihotri, N; Dutta, N; Gupta, S; Sarotra, P, 2007) |
| "Celecoxib is a potent nonsteroid antiinflammatory drug (NSAID) that has shown great promise in cancer chemoprevention and treatment." | 1.33 | Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. ( Chen, CS; D'Ambrosio, SM; Ding, H; Han, C; Zhu, J, 2005) |
| "Rofecoxib was withdrawn from the market worldwide because of concerns relating to cardiovascular safety." | 1.33 | Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme. ( Ashton, J; Harrison-Woolrych, M; Herbison, P; McLean, R; Slattery, J, 2005) |
| " With celecoxib, studies have shown that a 50% lower dosage is effective and causes fewer adverse effects." | 1.33 | How celecoxib could be safer, how valdecoxib might have been. ( Cohen, JS, 2005) |
| " Compared with long-term ibuprofen use, long-term use of celecoxib (adjusted hazard ratio [HR] 3." | 1.33 | Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. ( Barner, JC; Busti, AJ; Lawson, KA; Motsko, SP; Rascati, KL; Wilson, JP; Worchel, J, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 104 (72.22) | 29.6817 |
| 2010's | 36 (25.00) | 24.3611 |
| 2020's | 4 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Bechmann, N | 1 |
| Kniess, T | 1 |
| Köckerling, M | 1 |
| Pigorsch, A | 1 |
| Steinbach, J | 1 |
| Pietzsch, J | 1 |
| Kishore, N | 1 |
| Kumar, P | 1 |
| Shanker, K | 1 |
| Verma, AK | 1 |
| Obeid, S | 1 |
| Libby, P | 4 |
| Husni, E | 1 |
| Wang, Q | 3 |
| Wisniewski, LM | 3 |
| Davey, DA | 1 |
| Wolski, KE | 3 |
| Xia, F | 1 |
| Bao, W | 3 |
| Walker, C | 1 |
| Ruschitzka, F | 3 |
| Nissen, SE | 5 |
| Lüscher, TF | 4 |
| Schmidt, M | 1 |
| Sørensen, HT | 1 |
| Pedersen, L | 1 |
| Saxena, P | 1 |
| Sharma, PK | 1 |
| Purohit, P | 1 |
| Cheng, S | 1 |
| Xin, M | 1 |
| Zhou, J | 1 |
| Cheng, Y | 1 |
| Xu, G | 1 |
| Zhou, Y | 1 |
| Li, Z | 1 |
| Liang, F | 1 |
| Raschle, J | 1 |
| Chan, FKL | 1 |
| Ching, JYL | 1 |
| Tse, YK | 1 |
| Lam, K | 1 |
| Wong, GLH | 1 |
| Ng, SC | 1 |
| Lee, V | 1 |
| Au, KWL | 1 |
| Cheong, PK | 1 |
| Suen, BY | 1 |
| Chan, H | 1 |
| Kee, KM | 1 |
| Lo, A | 1 |
| Wong, VWS | 1 |
| Wu, JCY | 1 |
| Kyaw, MH | 1 |
| Antman, EM | 1 |
| Woo, Y | 1 |
| Hyun, MK | 1 |
| Ganju, J | 1 |
| Rom, D | 1 |
| Solomon, DH | 4 |
| Husni, ME | 4 |
| Borer, JS | 4 |
| Graham, DY | 3 |
| Lincoff, AM | 3 |
| Menon, V | 2 |
| Yeomans, ND | 3 |
| Berger, MF | 2 |
| Ricciotti, E | 1 |
| Castro, C | 1 |
| Tang, SY | 1 |
| Briggs, WTE | 1 |
| West, JA | 1 |
| Malik, D | 1 |
| Rhoades, SD | 1 |
| Meng, H | 1 |
| Li, X | 1 |
| Lahens, NF | 1 |
| Sparks, JA | 1 |
| Karlson, EW | 1 |
| Weljie, AM | 1 |
| Griffin, JL | 1 |
| FitzGerald, GA | 5 |
| Martín Arias, LH | 1 |
| Martín González, A | 1 |
| Sanz Fadrique, R | 1 |
| Vazquez, ES | 1 |
| Aschenbrenner, DS | 1 |
| Kelly, JD | 1 |
| Tan, WS | 1 |
| Porta, N | 1 |
| Mostafid, H | 1 |
| Huddart, R | 1 |
| Protheroe, A | 1 |
| Bogle, R | 1 |
| Blazeby, J | 1 |
| Palmer, A | 1 |
| Cresswell, J | 1 |
| Johnson, M | 1 |
| Brough, R | 1 |
| Madaan, S | 1 |
| Andrews, S | 1 |
| Cruickshank, C | 1 |
| Burnett, S | 1 |
| Maynard, L | 1 |
| Hall, E | 1 |
| Prozzi, GR | 1 |
| Cañás, M | 1 |
| Urtasun, MA | 1 |
| Buschiazzo, HO | 1 |
| Dorati, CM | 1 |
| Mordujovich-Buschiazzo, P | 1 |
| Shao, M | 1 |
| Wolski, K | 2 |
| Nissen, S | 1 |
| Paynter, N | 1 |
| Baselyous, Y | 1 |
| De Cocinis, M | 1 |
| Ibrahim, M | 1 |
| Kalra, A | 1 |
| Yacoub, R | 1 |
| Ahmed, R | 1 |
| Reed, GW | 1 |
| Krasselt, M | 1 |
| Baerwald, C | 1 |
| Kraus, S | 1 |
| Hummler, S | 1 |
| Toriola, AT | 1 |
| Poole, EM | 1 |
| Scherer, D | 1 |
| Kotzmann, J | 1 |
| Makar, KW | 1 |
| Kazanov, D | 1 |
| Galazan, L | 1 |
| Naumov, I | 1 |
| Coghill, AE | 1 |
| Duggan, D | 1 |
| Gigic, B | 1 |
| Arber, N | 4 |
| Ulrich, CM | 1 |
| Sifferlin, A | 1 |
| Chen, J | 1 |
| Shen, P | 1 |
| Zhang, XC | 1 |
| Zhao, MD | 1 |
| Zhang, XG | 1 |
| Yang, L | 1 |
| De Vecchis, R | 1 |
| Baldi, C | 1 |
| Di Biase, G | 1 |
| Ariano, C | 1 |
| Cioppa, C | 1 |
| Giasi, A | 1 |
| Valente, L | 1 |
| Cantatrione, S | 1 |
| Vlachopoulos, C | 1 |
| Aznaouridis, K | 1 |
| Bratsas, A | 1 |
| Ioakeimidis, N | 1 |
| Dima, I | 1 |
| Xaplanteris, P | 1 |
| Stefanadis, C | 1 |
| Tousoulis, D | 1 |
| Hung, SC | 1 |
| Hung, SR | 1 |
| Lin, CL | 1 |
| Lai, SW | 1 |
| Hung, HC | 1 |
| Thompson, PA | 1 |
| Ashbeck, EL | 1 |
| Roe, DJ | 1 |
| Fales, L | 1 |
| Buckmeier, J | 1 |
| Wang, F | 1 |
| Bhattacharyya, A | 1 |
| Hsu, CH | 1 |
| Chow, SH | 1 |
| Ahnen, DJ | 1 |
| Boland, CR | 1 |
| Heigh, RI | 1 |
| Fay, DE | 1 |
| Hamilton, SR | 1 |
| Jacobs, ET | 1 |
| Martinez, EM | 1 |
| Alberts, DS | 1 |
| Lance, P | 2 |
| Tam, HW | 1 |
| Yeo, KJ | 1 |
| Leong, PY | 1 |
| Chen, CH | 1 |
| Li, YC | 1 |
| Ma, CM | 1 |
| Wang, YH | 1 |
| Chiou, JY | 1 |
| Wei, JC | 1 |
| Gaffney, M | 1 |
| Beckerman, B | 1 |
| González-Gay, MA | 1 |
| González-Juanatey, C | 1 |
| Feng, GS | 1 |
| Ma, JL | 1 |
| Wong, BC | 1 |
| Zhang, L | 1 |
| Liu, WD | 1 |
| Pan, KF | 1 |
| Shen, L | 1 |
| Zhang, XD | 1 |
| Li, J | 1 |
| Xia, HH | 1 |
| Li, JY | 1 |
| Lam, SK | 1 |
| You, WC | 1 |
| Falk, GW | 1 |
| Jankowski, J | 1 |
| Hur, C | 1 |
| Broughton, DE | 1 |
| Ozanne, E | 1 |
| Yachimski, P | 1 |
| Nishioka, NS | 1 |
| Gazelle, GS | 1 |
| Falandry, C | 1 |
| Debled, M | 1 |
| Bachelot, T | 1 |
| Delozier, T | 1 |
| Crétin, J | 1 |
| Romestaing, P | 1 |
| Mille, D | 1 |
| You, B | 1 |
| Mauriac, L | 1 |
| Pujade-Lauraine, E | 1 |
| Freyer, G | 1 |
| Becker, MC | 1 |
| Wang, TH | 1 |
| Wisniewski, L | 1 |
| Mascette, AM | 1 |
| Krum, H | 2 |
| Dubois, RN | 1 |
| Bertagnolli, MM | 6 |
| Eagle, CJ | 4 |
| Zauber, AG | 6 |
| Redston, M | 2 |
| Breazna, A | 1 |
| Kim, K | 2 |
| Tang, J | 3 |
| Rosenstein, RB | 3 |
| Umar, A | 1 |
| Bagheri, D | 2 |
| Collins, NT | 1 |
| Burn, J | 2 |
| Chung, DC | 2 |
| Dewar, T | 2 |
| Foley, TR | 2 |
| Hoffman, N | 2 |
| Macrae, F | 2 |
| Pruitt, RE | 2 |
| Saltzman, JR | 2 |
| Salzberg, B | 2 |
| Sylwestrowicz, T | 2 |
| Hawk, ET | 4 |
| Kaneshiro, T | 1 |
| Okumura, M | 1 |
| Maalouf, S | 1 |
| Uflacker, A | 1 |
| Maruyama, T | 1 |
| Kawamori, T | 1 |
| Shapiro, MS | 1 |
| Simon, LS | 1 |
| White, WB | 2 |
| Bessette, L | 1 |
| Risebrough, N | 1 |
| Mittmann, N | 1 |
| Roussy, JP | 1 |
| Ho, J | 1 |
| Zlateva, G | 1 |
| Ray, WA | 1 |
| Varas-Lorenzo, C | 2 |
| Chung, CP | 1 |
| Castellsague, J | 2 |
| Murray, KT | 1 |
| Stein, CM | 1 |
| Daugherty, JR | 1 |
| Arbogast, PG | 1 |
| García-Rodríguez, LA | 1 |
| Hsiao, FY | 3 |
| Tsai, YW | 3 |
| Huang, WF | 3 |
| Montine, TJ | 1 |
| Sonnen, JA | 1 |
| Milne, G | 1 |
| Baker, LD | 1 |
| Breitner, JC | 1 |
| Hsu, M | 1 |
| Zaitone, SA | 1 |
| Moustafa, YM | 1 |
| Mosaad, SM | 1 |
| El-Orabi, NF | 1 |
| Chan, AT | 1 |
| Sima, CS | 1 |
| Ridker, PM | 1 |
| Bäck, M | 1 |
| Yin, L | 1 |
| Ingelsson, E | 1 |
| Skarke, C | 1 |
| Alamuddin, N | 1 |
| Lawson, JA | 1 |
| Cen, L | 1 |
| Propert, KJ | 1 |
| Wielage, R | 1 |
| Bansal, M | 1 |
| Wilson, K | 1 |
| Klein, R | 1 |
| Happich, M | 1 |
| Zhao, SZ | 1 |
| Burke, TA | 1 |
| Whelton, A | 1 |
| von Allmen, H | 1 |
| Henderson, SC | 1 |
| Sonnenblick, EH | 1 |
| Bing, RJ | 1 |
| Harley, C | 1 |
| Wagner, S | 1 |
| Spiegel, BM | 1 |
| Targownik, L | 1 |
| Dulai, GS | 1 |
| Gralnek, IM | 1 |
| Chiolero, A | 1 |
| Maillard, MP | 1 |
| Burnier, M | 2 |
| Stöllberger, C | 1 |
| Finsterer, J | 1 |
| Liew, D | 1 |
| Aw, J | 1 |
| Haas, S | 1 |
| Ding, H | 1 |
| Han, C | 1 |
| Zhu, J | 1 |
| Chen, CS | 1 |
| D'Ambrosio, SM | 1 |
| Lexchin, J | 1 |
| Mintzes, B | 1 |
| Couzin, J | 2 |
| Topol, EJ | 1 |
| Wolfe, MM | 1 |
| Meyer, CH | 1 |
| Cervi, D | 1 |
| Klement, G | 1 |
| Stempak, D | 1 |
| Baruchel, S | 1 |
| Koki, A | 1 |
| Ben-David, Y | 1 |
| Senior, K | 1 |
| Solomon, SD | 5 |
| McMurray, JJ | 2 |
| Pfeffer, MA | 2 |
| Wittes, J | 5 |
| Fowler, R | 4 |
| Finn, P | 2 |
| Anderson, WF | 2 |
| Zauber, A | 1 |
| Hawk, E | 3 |
| Bertagnolli, M | 1 |
| Psaty, BM | 2 |
| Furberg, CD | 1 |
| Drazen, JM | 1 |
| Bannwarth, B | 2 |
| Rawson, NS | 1 |
| Nourjah, P | 1 |
| Grosser, SC | 1 |
| Graham, DJ | 1 |
| Smith, ER | 1 |
| Laible, B | 1 |
| Okie, S | 1 |
| Evensen, S | 1 |
| Spigset, O | 1 |
| Slørdal, L | 1 |
| Cotter, J | 1 |
| Wooltorton, E | 1 |
| Maloney, DM | 1 |
| Harrison-Woolrych, M | 1 |
| Herbison, P | 1 |
| McLean, R | 1 |
| Ashton, J | 1 |
| Slattery, J | 1 |
| Albini, A | 1 |
| Noonan, DM | 1 |
| Brophy, JM | 2 |
| Bjarnason, NH | 1 |
| Cohen, JS | 1 |
| Messerli, FH | 1 |
| Sichrovsky, T | 1 |
| Araujo, LF | 1 |
| Soeiro, Ade M | 1 |
| Fernandes, Jde L | 1 |
| Serrano Júnior, CV | 1 |
| Allen, MJ | 1 |
| McLean-Veysey, P | 1 |
| Fleming, I | 1 |
| Oviedo, JA | 1 |
| Schroy, PC | 1 |
| Mathieu, C | 1 |
| Meier, P | 1 |
| Meyer zu Starten, A | 1 |
| Mayer, BJ | 1 |
| Lamfers, R | 1 |
| Feldstein, DA | 1 |
| Guo, ZR | 1 |
| Caldwell, B | 1 |
| Aldington, S | 1 |
| Weatherall, M | 1 |
| Shirtcliffe, P | 1 |
| Beasley, R | 1 |
| Wen, YW | 2 |
| Shih, YT | 1 |
| Dogné, JM | 1 |
| Hanson, J | 1 |
| Supuran, C | 1 |
| Pratico, D | 1 |
| Tegeder, I | 1 |
| Geisslinger, G | 1 |
| Sooriakumaran, P | 1 |
| Nelson, NJ | 1 |
| Motsko, SP | 1 |
| Rascati, KL | 1 |
| Busti, AJ | 1 |
| Wilson, JP | 1 |
| Barner, JC | 1 |
| Lawson, KA | 1 |
| Worchel, J | 1 |
| Cheung, R | 1 |
| Lowry, S | 1 |
| Maguire, A | 1 |
| Perez-Gutthann, S | 1 |
| Levin, B | 3 |
| Eagle, C | 1 |
| Lechuga, M | 1 |
| Corle, D | 1 |
| Hess, TM | 1 |
| Woloj, GM | 1 |
| Boisserie, F | 1 |
| Viner, JL | 1 |
| Gordon, GB | 1 |
| Spicak, J | 1 |
| Rácz, I | 1 |
| Dite, P | 1 |
| Hajer, J | 1 |
| Zavoral, M | 1 |
| Lechuga, MJ | 1 |
| Gerletti, P | 1 |
| Macdonald, K | 1 |
| Bhadra, P | 1 |
| Potter, JD | 1 |
| McGettigan, P | 1 |
| Henry, D | 1 |
| Marwali, MR | 1 |
| Mehta, JL | 1 |
| Sibilia, J | 1 |
| Deray, G | 2 |
| Montalescot, G | 1 |
| Valat, JP | 1 |
| Héloire, F | 1 |
| Armstrong, DJ | 1 |
| Andersohn, F | 2 |
| Suissa, S | 2 |
| Garbe, E | 2 |
| West, CR | 1 |
| Gorelick, PB | 1 |
| Lavange, L | 1 |
| Pan, SX | 1 |
| Weiner, E | 1 |
| Verburg, KM | 1 |
| Timmers, L | 1 |
| Sluijter, JP | 1 |
| Verlaan, CW | 1 |
| Steendijk, P | 1 |
| Cramer, MJ | 1 |
| Emons, M | 1 |
| Strijder, C | 1 |
| Gründeman, PF | 1 |
| Sze, SK | 1 |
| Hua, L | 1 |
| Piek, JJ | 1 |
| Borst, C | 1 |
| Pasterkamp, G | 1 |
| de Kleijn, DP | 1 |
| Jugdutt, BI | 1 |
| Tabrizchi, R | 1 |
| Futagami, S | 1 |
| Suzuki, K | 1 |
| Hiratsuka, T | 1 |
| Shindo, T | 1 |
| Hamamoto, T | 1 |
| Ueki, N | 1 |
| Kusunoki, M | 1 |
| Miyake, K | 1 |
| Gudis, K | 1 |
| Tsukui, T | 1 |
| Sakamoto, C | 1 |
| Depont, F | 1 |
| Fourrier, A | 1 |
| Merlière, Y | 1 |
| Droz, C | 1 |
| Amouretti, M | 1 |
| Bégaud, B | 1 |
| Bénichou, J | 1 |
| Moride, Y | 1 |
| Velo, GP | 1 |
| Sturkenboom, M | 1 |
| Blin, P | 1 |
| Moore, N | 1 |
| Cen, YY | 1 |
| Gupta, S | 1 |
| Sarotra, P | 1 |
| Aggarwal, R | 1 |
| Dutta, N | 1 |
| Agnihotri, N | 1 |
| Okayama, M | 1 |
| Hayashi, S | 1 |
| Aoi, Y | 1 |
| Nishio, H | 1 |
| Kato, S | 1 |
| Takeuchi, K | 1 |
| Anai, S | 1 |
| Tanaka, M | 1 |
| Shiverick, KT | 1 |
| Kim, W | 1 |
| Takada, S | 1 |
| Boehlein, S | 1 |
| Goodison, S | 1 |
| Mizokami, A | 1 |
| Rosser, CJ | 1 |
| Goldstein, JL | 1 |
| Cryer, B | 1 |
| Amer, F | 1 |
| Hunt, B | 1 |
| Jakobsen, A | 1 |
| Mortensen, JP | 1 |
| Bisgaard, C | 1 |
| Lindebjerg, J | 1 |
| Rafaelsen, SR | 1 |
| Bendtsen, VO | 1 |
| Targownik, LE | 1 |
| Metge, CJ | 1 |
| Leung, S | 1 |
| Chateau, DG | 1 |
| Fleischmann, R | 1 |
| Tannenbaum, H | 1 |
| Patel, NP | 1 |
| Notter, M | 1 |
| Sallstig, P | 1 |
| Reginster, JY | 1 |
| Finn, PV | 1 |
| Viner, J | 1 |
| Meinert, CL | 1 |
| Martin, B | 1 |
| Pater, JL | 1 |
| Goss, PE | 1 |
| Obara, S | 1 |
| Chew, EY | 1 |
| Kim, J | 1 |
| Arndt, G | 1 |
| Tive, L | 1 |
| Boers, M | 1 |
| Patrono, C | 2 |
| Patrignani, P | 1 |
| García Rodríguez, LA | 1 |
| Moodley, I | 1 |
| Gotlieb, D | 1 |
| Comarow, A | 1 |
| Sharma, RA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen[NCT00346216] | Phase 4 | 24,081 participants (Actual) | Interventional | 2006-10-04 | Completed | ||
| A Double-blind Randomized Comparison of Celecoxib Plus Esomeprazole Versus Naproxen Plus Esomeprazole for Prevention of Recurrent Ulcer Bleeding in Patients With Arthritis and Cardiothrombotic Diseases (NSAID#8 Study)[NCT00153660] | Phase 3 | 514 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Single Dose Oral Celecoxib (With or Without Acetaminophen) for Acute Post-operative Pain Following Impacted Third Molar Surgery.[NCT04790812] | Phase 4 | 100 participants (Anticipated) | Interventional | 2021-04-22 | Recruiting | ||
| Use of a Self-Guided Mindfulness Mobile Application to Improve Pain Outcomes in Individuals With Knee Osteoarthritis[NCT03936088] | 75 participants (Actual) | Interventional | 2019-05-02 | Completed | |||
| A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001[NCT03115073] | Phase 2/Phase 3 | 84 participants (Actual) | Interventional | 2017-04-04 | Completed | ||
| Prevention of Sporadic Colorectal Adenomas With Celecoxib[NCT00005094] | Phase 3 | 1,170 participants (Anticipated) | Interventional | 2000-03-31 | Completed | ||
| A Single Center, Double-blind, Placebo-controlled Phase I Single-dose Cross-over Study in Healthy Subjects to Investigate the Inhibitory Effect of CG100649, Celecoxib, Naproxen, and Acetazolamide on the Activity of Cyclooxygenases (COX-1, COX-2) and Carbo[NCT00780325] | Phase 1 | 26 participants (Actual) | Interventional | 2008-10-31 | Terminated (stopped due to A total of three parts were planned for this study. The sponsor funded only Part 1, so that neither Part 2 nor Part 3 of this study has been conducted.) | ||
| Efficacy of Intra-Articular Injection of Etanercept for Moderate and Severe Knee Osteoarthritis[NCT02722772] | 60 participants (Anticipated) | Interventional | 2016-02-29 | Recruiting | |||
| Efficacy of Subcutaneous Injection of Etanercept for Moderate and Severe Knee Osteoarthritis[NCT02722811] | 60 participants (Anticipated) | Interventional | 2016-02-29 | Recruiting | |||
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)[NCT00141193] | Phase 3 | 1,561 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of Lansoprazole 30 mg QD and Naproxen 500 mg BID Versus Celecoxib 200 mg QD in Risk Reduction of Non Steroidal Anti-Inflammatory-Associated Ulcers in Osteoarthritis Subjects Taki[NCT00175032] | Phase 3 | 1,045 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| A 52-week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability and Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid and Celecoxib 200 mg od in [NCT00145301] | Phase 3 | 3,036 participants | Interventional | 2004-09-30 | Completed | ||
| Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)[NCT00007189] | Phase 3 | 2,625 participants | Interventional | 2001-01-31 | Completed | ||
| Preliminary Multi-Center Assessment of Laser and Medical Treatment of Diabetic Macular Edema[NCT00050479] | Phase 3 | 100 participants | Interventional | 2002-12-31 | Completed | ||
| Quality Of Life Companion Study For JMA27 (NCIC-MA.27): A Randomized Phase III Trial Of Exemestane Versus Anastrozole With Or Without Celecoxib In Postmenopausal Women With Receptor Positive Primary Breast Cancer[NCT00090974] | 0 participants | Observational | 2005-01-26 | Completed | |||
| Phase III Study of the Effects of Selenium on Adenomatous Polyp Recurrence[NCT00078897] | Phase 3 | 1,621 participants (Actual) | Interventional | 2005-01-20 | Terminated (stopped due to Concluded - Terminated by PI) | ||
| A Placebo-Controlled, Double-Blind, Randomized Study of the Potential Interaction Between Aspirin and Ibuprofen or Celecoxib.[NCT00565500] | Phase 4 | 24 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Clinical Phase II Pilot Study of the Efficacy of FANG(30) to Treat Active Rheumatoid Arthritis in Adult Patients[NCT00749645] | Phase 2 | 60 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"VAS question How much pain do you have was graded on a scale from 0 to 100 with 0 indicating No pain and 100 indicating Worst possible pain." (NCT00346216)
Timeframe: ITT and MITT Population - Baseline to 42 months
| Intervention | Number of participants (Mean) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (ITT) N= 8014, 8001, 7928 | Change-Baseline to Mon1 (ITT) N=7382, 7379, 7325 | Change-Baseline to Mon2 (ITT) N=7180, 7090, 7149 | Change-Baseline to Mon4 (ITT) N=6777, 6696, 6740 | Change-Baseline to Mon8 (ITT) N=6230, 6137, 6159 | Change-Baseline to Mon12 (ITT) N=5792, 5696, 5846 | Change-Baseline to Mon18 (ITT) N=5310, 5181. 5246 | Change-Baseline to Mon24 (ITT) N=4818, 4776, 4785 | Change-Baseline to Mon30 (ITT) N=4140, 4069, 4086 | Change-Baseline to Mon36 (ITT) N=3692, 3627, 3635 | Change-Baseline to Mon42 (ITT) N=3469, 3406, 3439 | Baseline (MITT) N=7974, 7954, 7894 | Change-Baseline to Mon1 MITT N=7372, 7367, 7321 | Change-Baseline to Mon2 MITT N=7170, 7078, 7142 | Change-Baseline to Mon4 MITT N=6772, 6686, 6732 | Change-Baseline to Mon8 MITT N=6224, 6128, 6155 | Change-Baseline to Mon12 MITT N=5787, 5689, 5844 | Change-Baseline to Mon18 MITT N=5305, 5175, 5242 | Change-Baseline to Mon24 MITT N=4815, 4769, 4782 | Change-Baseline to Mon30 MITT N=4139, 4067, 4085 | Change-Baseline to Mon36 MITT N=3691, 3623, 3635 | Change-Baseline to Mon42 MITT N=3468, 3404, 3438 | |
| Celecoxib | 54.0 | -8.2 | -10.5 | -11.4 | -11.7 | -11.0 | -11.3 | -11.3 | -10.5 | -10.1 | -11.4 | 54.0 | -8.2 | -10.5 | -11.4 | -11.7 | -11.0 | -11.3 | -11.4 | -10.5 | -10.2 | -11.4 |
| Ibuprofen | 54.1 | -9.0 | -10.6 | -11.7 | -12.1 | -11.6 | -11.3 | -11.5 | -11.2 | -10.7 | -11.1 | 54.1 | -9.0 | -10.6 | -11.7 | -12.1 | -11.6 | -11.3 | -11.5 | -11.2 | -10.7 | -11.1 |
| Naproxen | 54.1 | -9.9 | -11.1 | -12.3 | -12.1 | -11.9 | -11.7 | -11.4 | -11.3 | -11.6 | -12.1 | 54.1 | -9.9 | -11.1 | -12.3 | -12.1 | -11.9 | -11.7 | -11.3 | -11.3 | -11.6 | -12.1 |
MACE defined as the composite of CV death (including hemorrhagic death), non-fatal MI, non-fatal stroke, hospitalization for UA, revascularization or hospitalization for TIA (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 4.2 | 3.1 |
| Ibuprofen | 4.8 | 3.6 |
| Naproxen | 4.3 | 3.2 |
APTC events are defined as a composite of any of the following events: Death due to CV causes (including cardiac, cerebrovascular, venous thromboembolic, haemorrhagic, other vascular, or unknown cause); Non-fatal MI; Non-fatal stroke (including intracranial hemorrhages, stroke of ischemic or unknown etiology). (NCT00346216)
Timeframe: Intent to Treat (ITT) Population - 30 months; Modified ITT (MITT) Population - 42 months
| Intervention | Percentage of Partcipants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 2.3 | 1.7 |
| Ibuprofen | 2.7 | 1.9 |
| Naproxen | 2.5 | 1.8 |
CSGIE include: Gastroduodenal (GD) hemorrhage, Gastric outlet obstruction, Gastroduodenal, small bowel or large bowel perforation, Large bowel hemorrhage, Small bowel hemorrhage, Acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage, Symptomatic gastric or duodenal ulcer (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 0.7 | 0.3 |
| Ibuprofen | 0.9 | 0.7 |
| Naproxen | 0.7 | 0.7 |
Adequate adherence to long-term selenium treatment as measured by blood selenium levels (ng/mL) at one year. (NCT00078897)
Timeframe: One year
| Intervention | ng/mL (Median) |
|---|---|
| Selenium | 205.4 |
| Placebo | 140.0 |
Detection of metachronous colorectal adenomas during follow-up, by treatment, in the original cohort. Surveillance colonoscopy is recommended 3 to 5 years after removal of colorectal adenoma(s). Participants will remain on the study intervention until their surveillance colonoscopy. Surveillance colonoscopy is determined by participants' GI physician. (NCT00078897)
Timeframe: 3 to 5 years after baseline colonoscopy
| Intervention | Adenomas (Number) |
|---|---|
| Selenium | 302 |
| Placebo | 295 |
40 reviews available for celecoxib and Cardiovascular Diseases
| Article | Year |
|---|---|
Human disorders associated with inflammation and the evolving role of natural products to overcome.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biological Products; Cardiovascular | 2019 |
A journey of celecoxib from pain to cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Humans; Inflam | 2020 |
Evaluating the Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiotoxicity; Cardiovascular Diseases; Celecox | 2017 |
Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs and Classical and Selective Cyclooxygenase-2 Inhibitors: A Meta-analysis of Observational Studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; C | 2019 |
[Cardiovascular risk of non-steroidal anti-inflammatory drugs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Drug Interacti | 2018 |
Celecoxib for the treatment of musculoskeletal arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; | 2019 |
Efficacy and safety profile of celecoxib for treating advanced cancers: a meta-analysis of 11 randomized clinical trials.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cardiovascul | 2014 |
Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibi | 2014 |
Celecoxib safety revisited.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cli | 2016 |
New, long-term insights from the Adenoma Prevention with Celecoxib Trial on a promising but troubled class of drugs.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cardiovascular System; Ce | 2009 |
An ion channel hypothesis to explain divergent cardiovascular safety of cyclooxygenase-2 inhibitors: the answer to a hotly debated puzzle?
Topics: Animals; Cardiovascular Agents; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase | 2009 |
COX-2 selective inhibitors and heart health.
Topics: Adult; Cardiovascular Diseases; Celecoxib; Child; Cyclooxygenase 2 Inhibitors; Humans; Hypertension; | 2005 |
Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective.
Topics: Age Factors; Aged; Amitriptyline; Analgesics; Cardiovascular Diseases; Celecoxib; Chronic Disease; C | 2013 |
Differences between COX-2-specific inhibitors: clinical and economic implications.
Topics: Aged; Blood Pressure; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibit | 2002 |
Cyclooxygenase-2 inhibitors: is there an association with coronary or renal events?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Celecoxib; Cycloox | 2003 |
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; | 2003 |
Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Cardiovascular Diseases; Ce | 2002 |
Cardiovascular effects of selective cyclooxygenase-2 inhibitors.
Topics: Cardiotonic Agents; Cardiovascular Diseases; Cardiovascular System; Celecoxib; Clinical Trials as To | 2004 |
[COX-2 inhibitors--one step forward and two steps back].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibito | 2005 |
Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Celecoxib; Cycloox | 2005 |
[Cardiovascular events: a class effect by COX-2 inhibitors].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibi | 2005 |
Celecoxib and cardiovascular risks.
Topics: Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Dose-Respon | 2005 |
[Do selective COX-2 inhibitors have adverse renal and cardiovascular effects?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibi | 2005 |
[Innovation of anti-inflammatory drugs--inhibition of cyclooxygenases].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 1; Cyclo | 2005 |
Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Prognosis; Pyrazoles; Rando | 2006 |
Coxibs and cardiovascular side-effects: from light to shadow.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase | 2006 |
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?
Topics: Cardiovascular Diseases; Celecoxib; Cell Proliferation; Clinical Trials as Topic; Cyclooxygenase Inh | 2006 |
COX-2 inhibitors and the heart: are all coxibs the same?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibi | 2006 |
Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibi | 2006 |
COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies.
Topics: Animals; Blood Platelets; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inh | 2006 |
[What do we know about the cardiovascular toxicity of the NSAIDs?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celeco | 2006 |
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas | 2006 |
Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celeco | 2007 |
Chemopreventive effect of celecoxib in gastric cancer.
Topics: Animals; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Gastric | 2007 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Follow-Up Studies; Humans; Pyrazole | 2008 |
Celecoxib clinical profile.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2000 |
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cardiova | 2001 |
The coxibs, selective inhibitors of cyclooxygenase-2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena | 2001 |
The coxibs, selective inhibitors of cyclooxygenase-2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena | 2001 |
The coxibs, selective inhibitors of cyclooxygenase-2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena | 2001 |
The coxibs, selective inhibitors of cyclooxygenase-2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena | 2001 |
Translational medicine: targetting cyclo-oxygenase isozymes to prevent cancer.
Topics: Arachidonic Acid; Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; C | 2002 |
Considerations for the safe prescribing and use of COX-2-specific inhibitors.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase In | 2002 |
25 trials available for celecoxib and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; | 2022 |
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Double-Blind Method; Drug Therapy, | 2017 |
Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cardiovascular | 2017 |
Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2018 |
BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004).
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherap | 2019 |
Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2019 |
Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Col | 2013 |
Arterial stiffening and systemic endothelial activation induced by smoking: The role of COX-1 and COX-2.
Topics: Adult; Analysis of Variance; Aspirin; Cardiovascular Diseases; Celecoxib; Cross-Over Studies; Cycloo | 2015 |
Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial.
Topics: Adenoma; Aged; Cardiovascular Diseases; Celecoxib; Colonoscopy; Colorectal Neoplasms; Cyclooxygenase | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention.
Topics: Adult; Cardiovascular Diseases; Celecoxib; China; Cyclooxygenase 2 Inhibitors; Dose-Response Relatio | 2008 |
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Aromatase I | 2009 |
Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena | 2009 |
Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Colonoscopy; Colorectal | 2009 |
Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT.
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, | 2010 |
Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cardiovascular Diseases; Celecoxib; | 2010 |
C-reactive protein and risk of colorectal adenoma according to celecoxib treatment.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; C-Reactive Protein; Cardiovascular | 2011 |
Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649.
Topics: 6-Ketoprostaglandin F1 alpha; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Area Under | 2012 |
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Colorectal N | 2005 |
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Colorectal N | 2005 |
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Colorectal N | 2005 |
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Colorectal N | 2005 |
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Colorectal N | 2005 |
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Colorectal N | 2005 |
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Colorectal N | 2005 |
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Colorectal N | 2005 |
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Colorectal N | 2005 |
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
Topics: Adenoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Car | 2006 |
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
Topics: Adenoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Car | 2006 |
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
Topics: Adenoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Car | 2006 |
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
Topics: Adenoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Car | 2006 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2006 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2006 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2006 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2007 |
A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cardiovascular | 2008 |
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.
Topics: Aged; Arthralgia; Canada; Cardiovascular Diseases; Celecoxib; Chemical and Drug Induced Liver Injury | 2008 |
79 other studies available for celecoxib and Cardiovascular Diseases
| Article | Year |
|---|---|
Novel (pyrazolyl)benzenesulfonamides with a nitric oxide-releasing moiety as selective cyclooxygenase-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzenesulfonamides; Cardiovascular Diseases; Cyclooxygenas | 2015 |
Cardiovascular Risks of Diclofenac Versus Other Older COX-2 Inhibitors (Meloxicam and Etodolac) and Newer COX-2 Inhibitors (Celecoxib and Etoricoxib): A Series of Nationwide Emulated Trials.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 | 2022 |
The cardiovascular risk of celecoxib for knee osteoarthritis: A protocol for systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Humans; Meta-Analysis a | 2020 |
Evaluation of cardiovascular risk associated with SKI306X use in patients with osteoarthritis and rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular D | 2017 |
Non-inferiority versus superiority drug claims: the (not so) subtle distinction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibi | 2017 |
Cyclooxygenase-2, Asymmetric Dimethylarginine, and the Cardiovascular Hazard From Nonsteroidal Anti-Inflammatory Drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arginine; Blood Pressure; Blood Urea Nitrogen; Car | 2018 |
Cardiovascular Risk of Celecoxib no Worse Than That of Ibuprofen or Naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Humans; Risk Factors | 2018 |
Potentially inappropriate concomitant medicine use with the selective COX-2 inhibitor celecoxib: Analysis and comparison of spontaneous adverse event reports from Australia, Canada and the USA.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Australia; Canada; Cardiovascular Diseases; Ce | 2019 |
NSAID choice: lessons from PRECISION.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Humans; Ibuprofen; Napr | 2019 |
More pain for painkillers.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase | 2013 |
Use of celecoxib correlates with increased relative risk of acute pancreatitis: a case-control study in Taiwan.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Alcohol-Related Disorders; Cardiovascular Diseases; C | 2015 |
Imprecision: Limitations to Interpretation of a Large Randomized Clinical Trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibi | 2017 |
Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib | 2017 |
Inflammation: NSAIDs and cardiovascular risk in arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Humans; Ibup | 2017 |
Chemoprevention and Barrett's esophagus: decisions, decisions.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc | 2008 |
Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc | 2008 |
Inhibition of prostaglandin E(2) signaling through the EP(1) receptor does not affect prostacyclin production in human endothelial cells.
Topics: Blood Coagulation; Bridged Bicyclo Compounds; Caproates; Cardiovascular Diseases; Celecoxib; Cell Li | 2009 |
Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2009 |
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; C | 2009 |
Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
Topics: Aged; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Factual; Drug Util | 2009 |
Effect of evening primrose oil and ω-3 polyunsaturated fatty acids on the cardiovascular risk of celecoxib in rats.
Topics: Animals; Blood Pressure; Cardiovascular Diseases; Celecoxib; Dietary Fats, Unsaturated; Fatty Acids, | 2011 |
Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.
Topics: Atrial Fibrillation; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Epidemiologic | 2012 |
Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cross-Sectional S | 2002 |
The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular D | 2003 |
[Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart].
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascu | 2003 |
Side effects of conventional nonsteroidal anti-inflammatory drugs and celecoxib: more similarities than differences.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibito | 2004 |
Coxibs and cardiovascular disease.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Dis | 2004 |
Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Apoptosis; Cardiovascular Diseases; Caspase 9; Caspase | 2005 |
Transparency in drug regulation: mirage or oasis?
Topics: Access to Information; Antidepressive Agents; Bias; Canada; Cardiovascular Diseases; Celecoxib; Clin | 2004 |
Clinical trials. Nail-biting time for trials of COX-2 drugs.
Topics: Alzheimer Disease; Anticarcinogenic Agents; Cardiovascular Diseases; Celecoxib; Controlled Clinical | 2004 |
Arthritis medicines and cardiovascular events--"house of coxibs".
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyc | 2005 |
Rofecoxib, Merck, and the FDA.
Topics: Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Approval; Drug Interact | 2004 |
[Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Colonic Polyps; Costs a | 2005 |
Targeting cyclooxygenase-2 reduces overt toxicity toward low-dose vinblastine and extends survival of juvenile mice with Friend disease.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cy | 2005 |
COX-2 inhibitors: cancer prevention or cardiovascular risk?
Topics: Adenoma; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxy | 2005 |
COX-2 inhibitors--lessons in drug safety.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase In | 2005 |
COX-2 inhibitors--a lesson in unexpected problems.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Dis | 2005 |
Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
Topics: Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cy | 2005 |
Do selective cyclo-oxygenase-2 inhibitors have a future?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibito | 2005 |
Factors associated with celecoxib and rofecoxib utilization.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; | 2005 |
Cyclooxygenase-2 inhibitors and cardiovascular risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Australia; Canada; Cardiovascular Diseases; Celecoxib; Cycl | 2005 |
COX-2 inhibitors and cardiovascular toxicity: a class effect?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibito | 2005 |
Raising the safety bar--the FDA's coxib meeting.
Topics: Advertising; Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular | 2005 |
New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra).
Topics: Canada; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Contraindications; Cyclooxygen | 2005 |
Institutional review boards must conduct safety review.
Topics: Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Clinical Trials Data Monitoring Commit | 2005 |
Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; F | 2005 |
Rescuing COX-2 inhibitors from the waste bin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Cardiovascular Diseases; Celecoxib; Cycloox | 2005 |
Cardiovascular risk associated with celecoxib.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Data Interpretation, Statistical; Hum | 2005 |
Inconsistency in the editorial process in Archives of Internal Medicine?
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Editorial Policies; Humans; Journalis | 2005 |
How celecoxib could be safer, how valdecoxib might have been.
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Industry; Humans; Isoxazoles; Py | 2005 |
Coxibs and cardiovascular risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cardiovascular Diseases; Celecoxib; Cli | 2005 |
Does celecoxib use increase the risk of cardiovascular events?
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Clinical Trial | 2005 |
COX-2 selective drugs and cardiovascular risks: same data but discrepant conclusions?
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Humans; Pyrazoles; Randomized Control | 2006 |
Clinical Questions #6. Does celecoxib increase cardiovascular risk?
Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Evidence-Based Medicine; Female; Hu | 2005 |
Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina Pectoris; Cardiovascular Diseases; Celecoxib; | 2006 |
Lessons to learn from the COX-2 saga. Yes, FDA reforms are needed. And marketing distorts how medications are used. But one moral to the story is that all drugs have risks.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibi | 2005 |
Celecoxib shown effective in preventing colon polyps.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Cardiovascular Diseases; Celecoxib | 2006 |
Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Stu | 2006 |
Celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibi | 2006 |
Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular D | 2007 |
Risks and benefits of celecoxib to prevent recurrent adenomas.
Topics: Adenoma; Adenomatous Polyps; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celec | 2006 |
Celecoxib and CVS risk--lessons from the APC and PreSAP studies.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Colorectal Neo | 2007 |
Risks and benefits of celecoxib to prevent colorectal adenomas.
Topics: Adenoma; Cardiovascular Diseases; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Huma | 2006 |
Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxy | 2006 |
Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig.
Topics: Animals; Blood Pressure; Cardiovascular Diseases; Celecoxib; Collagen; Cyclooxygenase 2; Cyclooxygen | 2007 |
Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular | 2006 |
Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Celecoxib | 2007 |
Cyclooxygenase inhibitors and cardiovascular risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Cel | 2007 |
Coxibs: can this class of drugs survive?
Topics: Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Evidence-Bas | 2005 |
Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxi | 2007 |
Letter by Cen regarding article, "Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas".
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Color | 2007 |
Role of oxidative stress in celecoxib-induced renal damage in wistar rats.
Topics: Animals; Biomarkers; Cardiovascular Diseases; Catalase; Celecoxib; Creatinine; Cyclooxygenase Inhibi | 2007 |
Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats.
Topics: Animals; Cardiovascular Diseases; Celecoxib; Colitis, Ulcerative; Colon; Cyclooxygenase 1; Cyclooxyg | 2007 |
Increased expression of cyclooxygenase-2 correlates with resistance to radiation in human prostate adenocarcinoma cells.
Topics: Adenocarcinoma; Blotting, Western; Cardiovascular Diseases; Celecoxib; Cell Line, Tumor; Cell Surviv | 2007 |
The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
Topics: Age Distribution; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cardiovascular Disease | 2008 |
NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cardiovascular Diseases; Celecoxib; Cycl | 2001 |
Celecoxib--the debate rages on.
Topics: Advertising; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Drug Appro | 2001 |
Celecoxib-- the debate ranges on.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Humans; Insurance Cover | 2001 |
Pain relief at a price. A blow to the heart?
Topics: Arthritis; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; | 2001 |